N/A
Completed N=507
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Source: ClinicalTrials.gov NCT06462014 ↗Enrolled (actual)
507
Serious AEs
—
Results posted
Dec 2025
Primary outcomePrimary: Number of Participants According to Geographic Region — 240; 94; 93; 80 Participants
Summary
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants According to Geographic Region |
240; 94; 93; 80 | — |
| PRIMARY Number of Participants According to Index Year |
0; 81; 203; 223 | — |
| PRIMARY Time From First Observed Prostate Cancer Diagnosis Date to the Index Date |
55.8 | — |
| PRIMARY Number of Participants According to Type of Previous Treatments Received |
103; 86; 77; 48; 46; 7 | — |
| PRIMARY Number of Participants According to Metastasis Status |
169; 338 | — |
| PRIMARY Number of Participants According to Site of Metastasis |
59; 34; 20; 20; 36 | — |
| PRIMARY Number of Participants According to Androgen Deprivation Therapy (ADT) Status |
80; 89; 286; 52 | — |
| PRIMARY Prostate-Specific Antigen (PSA) Value at 180 Days Prior to Index Date |
118.8 | — |
| PRIMARY Testosterone Value at 180 Days Prior to Index Date |
200.9 | — |
| PRIMARY Mean National Cancer Institute (NCI) Charlson Comorbidity Index (CCI) Score |
1.8 | — |
| PRIMARY Number of Participants According to Comorbidities |
357; 319; 168; 114; 90; 74 | — |
Eligibility Criteria
Inclusion Criteria
- Male with ≥ 1 diagnosis for PC
- Had ≥ 2 prescriptions of relugolix on or after the first observed PC diagnosis.
- Index date: the initiation date of relugolix
- At least 18 years old at the index date
Exclusion Criteria
- had surgical castration (bilateral orchiectomy) any time before the index date
Data sourced from ClinicalTrials.gov (NCT06462014). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.